Across TCGA pan-cancer cohorts, METTL7A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated METTL7A data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher METTL7A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated METTL7A expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where METTL7A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.751	0.502	.005	21	view →
CCRCC	OS	Median	III,IV	0.926	0.634	.002	18	view →
UCEC	DFS	Median	All	0.833	0.975	.005	16	view →
HNSC	OS	Median	II,III,IV	0.793	0.626	.031	1	view →
PDAC	OS	Tertile	III,IV	1.000	0.600	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: METTL7A tumor-vs-normal RNA expression · all METTL7A data types